Literature DB >> 1472060

The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity.

K Miyahara1, T Kawamoto, Y Mitsuuchi, K Toda, H Imura, R D Gordon, Y Shizuta.   

Abstract

Glucocorticoid-suppressible hyperaldosteronism (GSH) is one variety of primary aldosteronism with hypertension and is inherited in an autosomal dominant mode. A recent report has indicated that GSH is caused by a gene duplication arising from unequal crossing over between the two genes, CYP11B1 and CYP11B2, encoding P-450(11 beta) and P-450C18, respectively (Lifton et al. Nature (1992) 355, 262-265). The nucleotide sequence analysis in the present study has demonstrated that unequal crossing over in the chimeric gene formed by the gene duplication occurs within the region from the 3'-portion of exon 4 through the 5'-portion of intron 4 in Australian GSH patients. Namely, the chimeric gene encodes a fused P-450 protein consisting of the amino-terminal side of P-450(11 beta) (encoded by exons 1-4 of CYP11B1) and the carboxyl-terminal side of P-450C18 (encoded by exons 5-9 of CYP11B2). When a cDNA corresponding to the chimeric gene is transfected into COS-7 cells, the fused P-450 protein expressed in the mitochondria exhibits steroid 18-hydroxylase or aldosterone synthase activity. These results provide the molecular genetic basis for the characteristic biochemical phenotype of GSH patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472060     DOI: 10.1016/0006-291x(92)92286-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Detection of clinically relevant exonic copy-number changes by array CGH.

Authors:  Philip M Boone; Carlos A Bacino; Chad A Shaw; Patricia A Eng; Patricia M Hixson; Amber N Pursley; Sung-Hae L Kang; Yaping Yang; Joanna Wiszniewska; Beata A Nowakowska; Daniela del Gaudio; Zhilian Xia; Gayle Simpson-Patel; LaDonna L Immken; James B Gibson; Anne C-H Tsai; Jennifer A Bowers; Tyler E Reimschisel; Christian P Schaaf; Lorraine Potocki; Fernando Scaglia; Tomasz Gambin; Maciej Sykulski; Magdalena Bartnik; Katarzyna Derwinska; Barbara Wisniowiecka-Kowalnik; Seema R Lalani; Frank J Probst; Weimin Bi; Arthur L Beaudet; Ankita Patel; James R Lupski; Sau Wai Cheung; Pawel Stankiewicz
Journal:  Hum Mutat       Date:  2010-11-02       Impact factor: 4.878

2.  Variation of phenotype in patients with glucocorticoid remediable aldosteronism.

Authors:  L J Gates; A A MacConnachie; R P Lifton; N E Haites; N Benjamin
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

3.  The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone.

Authors:  L Pascoe
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

4.  Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree.

Authors:  L Pascoe; X Jeunemaitre; M C Lebrethon; K M Curnow; C E Gomez-Sanchez; J M Gasc; J M Saez; P Corvol
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 5.  Genetics and epigenetics of adrenocortical tumors.

Authors:  Antonio M Lerario; Andreas Moraitis; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2013-11-09       Impact factor: 4.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.